What is William Blair's Estimate for ResMed Q2 Earnings?

ResMed Inc. (NYSE:RMD - Free Report) - Analysts at William Blair issued their Q2 2025 earnings per share (EPS) estimates for shares of ResMed in a research note issued to investors on Wednesday, December 11th. William Blair analyst M. Andrew anticipates that the medical equipment provider will post earnings of $2.29 per share for the quarter. The consensus estimate for ResMed's current full-year earnings is $9.34 per share.

Other analysts have also issued research reports about the company. Needham & Company LLC restated a "hold" rating on shares of ResMed in a report on Friday, October 25th. Royal Bank of Canada upped their price objective on ResMed from $224.00 to $232.00 and gave the company a "sector perform" rating in a report on Friday, October 25th. Stifel Nicolaus began coverage on ResMed in a report on Friday. They issued a "hold" rating and a $250.00 price objective for the company. Baird R W upgraded ResMed to a "strong-buy" rating in a report on Tuesday, September 24th. Finally, Wolfe Research restated an "underperform" rating and issued a $180.00 price objective on shares of ResMed in a report on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $227.91.

ResMed Stock Performance

RMD stock traded up $2.50 during trading on Monday, reaching $241.02. 827,470 shares of the company's stock were exchanged, compared to its average volume of 1,018,335. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. ResMed has a 1-year low of $164.12 and a 1-year high of $260.49. The company's fifty day moving average price is $242.75 and its 200-day moving average price is $227.74. The firm has a market cap of $35.38 billion, a PE ratio of 31.59, a P/E/G ratio of 1.73 and a beta of 0.68.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same quarter in the previous year, the firm posted $1.64 EPS. The firm's quarterly revenue was up 11.1% on a year-over-year basis.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Thursday, November 7th were given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.88%. The ex-dividend date was Thursday, November 7th. ResMed's payout ratio is 28.08%.

Insider Activity at ResMed

In other news, CEO Michael J. Farrell sold 14,683 shares of the company's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $231.91, for a total transaction of $3,405,134.53. Following the completion of the sale, the chief executive officer now owns 464,169 shares in the company, valued at approximately $107,645,432.79. This represents a 3.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total value of $491,300.00. Following the sale, the director now owns 81,218 shares of the company's stock, valued at approximately $19,951,201.70. This trade represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,725 shares of company stock valued at $11,253,448. Company insiders own 0.71% of the company's stock.

Institutional Trading of ResMed

Several large investors have recently made changes to their positions in the stock. American Trust bought a new stake in ResMed during the 3rd quarter valued at approximately $690,000. Franklin Resources Inc. raised its holdings in shares of ResMed by 56.5% in the 3rd quarter. Franklin Resources Inc. now owns 174,113 shares of the medical equipment provider's stock worth $41,909,000 after buying an additional 62,882 shares in the last quarter. Tidal Investments LLC raised its holdings in shares of ResMed by 738.4% in the 3rd quarter. Tidal Investments LLC now owns 104,938 shares of the medical equipment provider's stock worth $25,617,000 after buying an additional 92,422 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in ResMed during the 3rd quarter valued at $193,000. Finally, World Investment Advisors LLC acquired a new stake in ResMed during the 3rd quarter valued at $541,000. Institutional investors own 54.98% of the company's stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.